Drugs / AN4035
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07686445 | Sep 2026 → Dec 2028 expected | — | Adlai Nortye Biopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AN4035 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07686445 ↗ |
| Known as | CAN4035 | “AN4035 is a CAN4035 is a CEACAM5-targeting ADC designed to selectively deliver a proprietary pan-RAS(ON) inhibitor payload to tumor cells.” NCT07686445 ↗ |
| Action | Inhibit | “pan-RAS(ON) inhibitor payload” NCT07686445 ↗ |
| Route | Intravenous | “AN4035 by intravenous (IV) infusion every 2 weeks” NCT07686445 ↗ |